驱动基因阳性局部晚期非小细胞肺癌靶向治疗序贯根治性放疗发生有症状放射性肺炎的风险因素分析

谭佩欣; 黄唯; 张红丹; 杜钦文; 潘燚

doi:10.12019/j.issn.1671-5144.2020.04.010

驱动基因阳性局部晚期非小细胞肺癌靶向治疗序贯根治性放疗发生有症状放射性肺炎的风险因素分析

广东省人民医院放疗科、广东省医学科学院, 广州 510080

基金项目: 广东省医学科学技术研究基金资助项目（B2020024）; 广东省人民医院国自然配套启动资金资助项目（8190120260）; 广东省人民医院院内启动基金资助项目（8197110946）; 吴阶平医学基金资助项目（320.6750.19089-1）

详细信息

作者简介:
谭佩欣（1988-）,女,广东佛山人,医师,博士研究生,从事肿瘤放射治疗研究。

通讯作者:
潘燚, Tel: 020-83827812, E-mail: panyiff01@163.com

中图分类号: R734.2
计量
- 文章访问数: 156
- HTML全文浏览量: 7
- PDF下载量: 130
出版历程
- 收稿日期: 2020-10-21
- 发布日期: 2020-08-27

Risk Factors of Symptomatic Radiation Pneumonitis in Patients With Driver Gene Positive Locally Advanced Non-Small Cell Lung Cancer After Targeted Therapy Followed by Sequential Radical Radiotherapy

Department of Radiotherapy, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

摘要

摘要: 目的评估驱动基因阳性局部晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）靶向治疗序贯根治性放疗有症状放射性肺炎（radiation pneumonitis,RP）的发生率及风险因素。方法回顾性分析2017年1月至2020年4月在广东省人民医院接受靶向治疗序贯胸部放疗的不可手术Ⅲ期NSCLC患者。采用不良反应评价标准5.0版进行RP分级,≥2级定义为有症状RP。使用Χ²检验以及Kruskal Wallis检验评估潜在的临床及剂量学危险因素。结果 13例入组患者,其中6例（46.1%）发生有症状RP。2级RP 5例,3级RP 1例。经激素治疗后所有RP均转归为肺纤维化1~2级。单因素分析结果显示年龄、慢性阻塞性肺炎病史等临床因素与≥2级RP不相关,V20、肺平均受量等剂量学因素均未见与≥2级RP相关。结论靶向治疗序贯胸部放疗后≥2级RP的发生率较高,未发现与有症状RP相关的临床或剂量学危险因素。
- 非小细胞肺癌 /
- 靶向治疗 /
- 放疗 /
- 放射性肺炎
Abstract: Objective To evaluate the incidence and risk factors of symptomatic radiation pneumonitis（RP） in patients with driver gene positive locally advanced non-small cell lung cancer（NSCLC）. Methods From January 2017 to April 2020, patients with inoperable stageⅢ NSCLC who received targeted therapy followed by sequential thoracic radiotherapy in Guangdong Provincial People's Hospital were retrospectively analyzed. Radiation pneumonitis was graded according to the common terminology criteria for adverse events 5.0. The symptomatic RP was defined as ≥ grade 2. Chi square test and nonparametric Kruskal Wallis test were used to evaluate the potential clinical and dosimetric risk factors. Results Among the 13 patients, 6 （46.1%） had symptomatic RP. There were 5 cases of ≥ grade 2 RP and 1 case of grade 3 RP. After steroid treatment, all RP were recovered and resulted in pulmonary fibrosis grade 1~2. Univariate analysis showed that age, history of chronic obstructive pneumonia and other clinical factors were not associated with ≥ grade 2 RP. Dose factors such as V20 and average lung dose were not related to ≥ grade 2 RP. Conclusion The incidence of ≥ grade 2 RP after targeted therapy followed by sequential radiotherapy is high. No clinical or dosimetric risk factors related to symptomatic RP were found.
- non-small cell lung cancer /
- targeted therapy /
- radiotherapy /
- radiation pneumonitis

HTML全文

参考文献(19)

[1]	AUPÉRIN A, LE PÉCHOUX C, ROLLAND E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13): 2181-2190.
[2]	YOON S M, SHAIKH T, HALLMAN M.Therapeutic management options for stage Ⅲ non-small cell lung cancer[J]. World J Clin Oncol, 2017, 8(1): 1-20.
[3]	BRADLEY J D, PAULUS R, KOMAKI R, et al.Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015, 16(2): 187-199.
[4]	ZHONG W Z, CHEN K N, CHEN C, et al.Erlotinib Versus Gemcitabine plus Cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): A randomized phase Ⅱ study[J]. J Clin Oncol, 2019, 37(25):2235-2245.
[5]	ZHONG W Z, WANG Q, MAO W M, et al.Gefitinib versus Vinorelbine plus Cisplatin as adjuvant treatment for stageⅡ-ⅢA(N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): A randomised, open-label, phase 3 stud[J]. Lancet Oncol, 2018, 19(1):139-148.
[6]	QI W X, SUN Y J, SHEN Z, et al.Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase Ⅲ clinical trials[J]. J Chemother, 2015, 27(1): 40-51.
[7]	ABDEL-RAHMAN O, ELHALAWANI H.Risk of fatal pulmonary events in patients with advanced non-small cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: A comparative meta-analysis[J]. Future Oncol, 2015, 11(7): 1109-1122.
[8]	AKAMATSU H, INOUE A, MITSUDOMI T, et al.Interstitial lung disease associated with Gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: Combined analysis of two Phase Ⅲ trials (NEJ 002 and WJTOG 3405)[J]. Jpn J Clin Oncol, 2013, 43(6):664-668.
[9]	CURRAN W J JR, PAULUS R, LANGER C J, et al, Sequential vs concurrent chemoradiation for stage Ⅲ non-small cell lung cancer: Randomized phase Ⅲ trial RTOG 9410[J]. J Natl Cancer Ins, 2011, 103(19):1452-1460.
[10]	PALMA D A, SENAN S, TSUJINO K, et al.Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2013, 85(2): 444-450.
[11]	RODRIGUES G, LOCK M, D'SOUZA D, et al. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review[J]. Radiother Oncol, 2004, 71(2):127-138.
[12]	ZHAO L, JI W, OU G, et al.Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy[J]. Lung Cancer, 2012, 77(2): 326-330.
[13]	ANTONIA S J, VILLEGAS A, DANIEL D, et al.Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929.
[14]	FU Z, YANG X, WANG W, et al.Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: A phaseⅡclinical trial[J]. Radiat Oncol, 2020, 15(1): 155.
[15]	KOMAKI R, ALLEN P K, WEI X, et al.Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage Ⅲ non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 92(2): 317-324.
[16]	WANG J, XIA T Y, WANG Y J, et al.Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(3): e59-e65.
[17]	VOGELIUS I R, BENTZEN S M.A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis[J]. Acta Oncol, 2012, 51(8): 975-983.
[18]	TUCKER S L, LIU H H, LIAO Z, et al.Analysis of radiation pneumonitis risk using a generalized Lyman model[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2): 568-574.
[19]	GRAHAM M V, PURDY J A, EMAMI B, et al.Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)[J]. Int J Radiat Oncol Biol Phys, 1999, 45(2): 323-329.